Sensei Biotherapeutics
We have no price for Sensei Biotherapeutics since 17 July 2026. It may have been taken over, merged or renamed, so the figures below are from then.
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
We do not have this company's yearly figures yet, so its profit, growth, price and debt cannot be judged here.
Money in, money out
What Sensei Biotherapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$21.1 million of profit last year.
Sensei Biotherapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Sensei Biotherapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Sensei Biotherapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -50 | -37 | -32 | -22 | |
| -47 | -33 | -29 | -21 | |
| -49 | -34 | -30 | -21 | |
| -31.60 | -24.40 | -24.00 | -16.72 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 118 | 74 | 45 | 23 |
| Cash | 18 | 13 | 10 | 9 |
| Total debt | 8 | 6 | 4 | 2 |
| Total liabilities | 15 | 9 | 7 | 4 |
| 103 | 65 | 38 | 19 | |
| 2 | 1 | 1 | 1 | |
| -34.3% | -37.7% | -56.2% | -82.7% | |
| -47.0% | -52.5% | -78.6% | -113.4% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -39 | -32 | -25 | -20 | |
| 0 | 0 | 0 | 0 | |
| -39 | -32 | -25 | -20 | |
| Dividends paid | – | – | – | – |
| 0 | 10 | 0 | 0 | |
| 6 | 4 | 3 | 1 |
Valuation
- –
- –
- –
- –
- –
- –
- –
- –
- –
- –
Profitability
- –
- –
- –
- –
- –
- –
- –
- –
- –
- –
Growth
- –
- –
- –
- –
- –
Financial health
- –
- –
- –
- –
- –
- –
- –
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 15, 2026 | -131.45 | -0.62 | −21,101.6% |
| Mar 30, 2026 | -3.74 | -4.81 | +22.2% |
| Nov 14, 2025 | -3.62 | -4.11 | +11.9% |
| Aug 5, 2025 | -3.91 | -6.20 | +36.9% |
| May 6, 2025 | -5.40 | -4.20 | −28.6% |
| Mar 28, 2025 | -5.40 | -5.40 | +0.0% |
| Nov 14, 2024 | -5.80 | -6.20 | +6.5% |
| Aug 6, 2024 | -5.60 | -5.00 | −12.0% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/6Passes 0 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Questions about Sensei Biotherapeutics
Is Sensei Biotherapeutics a good stock to buy?
We do not have this company's yearly figures yet, so its profit, growth, price and debt cannot be judged here. 0 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Sensei Biotherapeutics AI analysis
What does Sensei Biotherapeutics do?
Sensei Biotherapeutics, Inc. (SNSE) is a biopharmaceutical firm dedicated to discovering and advancing immunotherapies, primarily for cancer treatment. The company's innovative approaches include its proprietary ImmunoPhage platform. It is in Biotechnology.
Does Sensei Biotherapeutics pay a dividend?
No. Sensei Biotherapeutics does not pay a dividend at the moment; in 2025 it returned $1,000 to shareholders by buying back its own shares.
Who are Sensei Biotherapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Sensei Biotherapeutics's.
Prices: daily closes to Jul 17, 2026. Fundamentals: company reports via invest-like data.